<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<headerData>
<submissionType>144</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001832794</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<issuerInfo>
<issuerCik>0001823239</issuerCik>
<issuerName>MARAVAI LIFESCIENCES HOLDINGS, INC.</issuerName>
<secFileNumber>001-39725</secFileNumber>
<issuerAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">10770 Wateridge Circle</street1>
<street2 xmlns="http://www.sec.gov/edgar/common">Suite 200</street2>
<city xmlns="http://www.sec.gov/edgar/common">San Diego</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">CA</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">92121</zipCode>
</issuerAddress>
<issuerContactPhone>858-546-0004</issuerContactPhone>
<nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Maravai Life Sciences Holdings 2, LLC</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
<relationshipsToIssuer>
<relationshipToIssuer>Owner</relationshipToIssuer>
</relationshipsToIssuer>
</issuerInfo>
<securitiesInformation>
<securitiesClassTitle>Class A common stock, par value $0.01 per share</securitiesClassTitle>
<brokerOrMarketmakerDetails>
<name>Goldman Sachs &amp; Co. LLC</name>
<address>
<street1 xmlns="http://www.sec.gov/edgar/common">200 West Street</street1>
<city xmlns="http://www.sec.gov/edgar/common">New York</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">NY</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">10282</zipCode>
</address>
</brokerOrMarketmakerDetails>
<noOfUnitsSold>1531028</noOfUnitsSold>
<aggregateMarketValue>16504481.84</aggregateMarketValue>
<noOfUnitsOutstanding>132830872</noOfUnitsOutstanding>
<approxSaleDate>05/28/2024</approxSaleDate>
<securitiesExchangeName>Nasdaq</securitiesExchangeName>
</securitiesInformation>
<securitiesToBeSold>
<securitiesClassTitle>Class A common stock, par value $0.01 per share</securitiesClassTitle>
<acquiredDate>11/19/2020</acquiredDate>
<natureOfAcquisitionTransaction>Pre-IPO reorganization</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Maravai LifeSciences Holdings, Inc.</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>28965664</amountOfSecuritiesAcquired>
<paymentDate>11/19/2020</paymentDate>
<natureOfPayment>Securities of the issuer were received in connection with a series of reorganization transactions prior to the issuer's IPO.</natureOfPayment>
</securitiesToBeSold>
<nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
<remarks>(1) Based on the closing price on May 28, 2024 of $10.78. (2) As of May 2, 2024 (as reported on the Issuer's Form 10-Q for the quarter ended March 31, 2024, filed with the Securities and Exchange Commission on May 9, 2024).</remarks>
<noticeSignature>
<noticeDate>05/28/2024</noticeDate>
<signature>/s/ Kevin Herde</signature>
</noticeSignature>
</formData>
</edgarSubmission>
